<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662686</url>
  </required_header>
  <id_info>
    <org_study_id>1506-IGX-042-AD</org_study_id>
    <nct_id>NCT02662686</nct_id>
  </id_info>
  <brief_title>Study for the Evaluation of &quot;MitoScore&quot; Marker in the Diagnosis of Embryo Viability in Euploids Embryos</brief_title>
  <acronym>MitoScore</acronym>
  <official_title>Randomized Multi-centric Prospective Study for the Evaluation of &quot;MitoScore&quot; Marker in the Diagnosis of Embryo Viability in Euploids Embryos.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of copies of mitochondrial genes (mtDNA or &quot;MitoScore&quot;) is related to the energy
      supply of the embryo, which can affect its ability to implant in the maternal uterus.

      The objective of this study is to analyse the potential of MitoScore before embryo transfer
      as a marker to identify and select the embryo with greater capacity of implantation. First of
      all, chromosomally normal embryos will be selected and mtDNA copies will be quantified.
      Finally, embryos with less copies of mtDNA will be considered for embryo transfer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of mitochondrial DNA copies (mtDNA) of a chromosomally normal embryo is related to
      a state of energy, which affects the ability of the embryo to implant in the maternal uterus.
      There is a decrease in the rate of implantation in euploid embryos containing a high number
      of mtDNA copies. It is known that after a certain number of mtDNA copies implantation is
      disrupted even in euploid embryos.

      The main purpose of this study is to evaluate the possible relationship between the mtDNA
      content contained in developing embryos and the result of implantation in order to evaluate
      the potential of such relationship as a diagnostic tool.

      The number of mtDNA copies present in chromosomally normal embryos will be quantified.
      Subsequently, the transfer of euploid embryos after the randomization will be using either
      routine morphological or MitoScore criteria.

      Study population: women undergoing either IVF or egg donation that go through preimplantation
      genetic screening (PGS) for different indications, either in day 5/6 or day 3.

      This is a triple blinded, randomized, prospective, clinical study where patients with embryos
      analyzed by PGS in blastocyst stage or day 3 and mitochondrial analysis with day 5/6
      transfer, with deferred cycle for those analyzed in day 5/6 and fresh embryo transfer for
      those analyzed in day 3, will be randomized into two groups:

      GROUP A: Embryo selection for transfer will be based initially on chromosomal normality and
      secondly on embryo morphology criteria (specific for IVF lab).

      GROUP B: Embryo selection for transfer will be based initially on chromosomal normality and
      secondly on the MitoScore value, trying to transfer normal embryos containing the lowest
      number of mitochondrial DNA copies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1718</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MitoScore</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer according to morphological criteria</intervention_name>
    <description>Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer according to the MitoScore results</intervention_name>
    <description>Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).</description>
    <arm_group_label>MitoScore</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  PGS cycles for different indications

               -  Maternal age: ≤40 years old (FIV/ICSI patients)

               -  Maternal age: &lt;50 years old (OVODON patients)

               -  Spermatocyte concentration: &gt; 2 million of spermatocyte/ml

               -  Single embryo transfer

                  -≥ 8 oocytes MII

               -  Number of Antral Follicules (AFC: ≥10 MII)

          -  Exclusion Criteria:

               -  Detection in the moment of inclusion or previous diagnosis of congenital uterine
                  malformations.

               -  Patients with embryo sex selection for those countries in which it is allowed.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Diez, BS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Igenomix</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Simon, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Igenomix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Las Palmas</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Aravaca</city>
        <state>Madrid</state>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Bilbao</name>
      <address>
        <city>Leioa</city>
        <state>Vizcaya</state>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Vigo</name>
      <address>
        <city>Pontevedra</city>
        <zip>35203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Igenomix</investigator_affiliation>
    <investigator_full_name>Antonio Diez</investigator_full_name>
    <investigator_title>Product Innovation Leader</investigator_title>
  </responsible_party>
  <keyword>Embryo Implantation</keyword>
  <keyword>Mitochondrial genes</keyword>
  <keyword>Mitochondrial DNA</keyword>
  <keyword>MitoScore</keyword>
  <keyword>Embryo selection</keyword>
  <keyword>Embryo viability</keyword>
  <keyword>Embryo biomarker</keyword>
  <keyword>Diagnosis of embryo viability in euploids embryos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

